ifosfamide has been researched along with Brain Diseases in 69 studies
Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 9.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 8.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 7.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "Methylene blue has been used not only as a diagnostic agent, but also as an agent in the treatment of ifosfamide-induced encephalopathy (IIE) for several years." | 5.38 | Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy. ( Fisher, DC; McDonnell, AM; Rybak, I; Wadleigh, M, 2012) |
| "The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 5.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
| "In summary, female sex, low total bilirubin, albumin and haemoglobin levels, and obesity appear to be associated with ifosfamide-induced encephalopathy." | 4.84 | Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. ( Beri, R; Shord, SS; Sweiss, KI, 2008) |
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 4.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "To determine whether thiamine prophylaxis decreases the incidence of ifosfamide-induced encephalopathy in patients receiving ifosfamide for the treatment of lymphoma." | 3.96 | Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. ( Ayarza, M; Clark, SM; Hairston, A; Lentz, KL; Liu, B; Morgan, KP; Wind, LS, 2020) |
| " This is a report of a 64-year-old female with relapsed double-hit diffuse large B-cell lymphoma who developed severe altered mental status and neurological symptoms after receiving a second dose of ifosfamide as part of her salvage standard dose R-IE (rituximab, ifosfamide, etoposide), in preparation for chimeric antigen receptor T-cell therapy." | 3.91 | Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy. ( Gharaibeh, EZ; Powers, BC; Salacz, ME; Telfah, M, 2019) |
| "A retrospective study of sarcoma and lymphoma patients receiving ifosfamide chemotherapy was performed at the participating institutions." | 3.81 | An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. ( Butrynski, J; Cirrone, F; Feng, Y; Fisher, DC; Harris, C; McDonnell, AM; Neuberg, D; Szabatura, AH; Voit, D, 2015) |
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 3.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "IFO-induced encephalopathy (IIE) is one of the serious side effects, but there is not enough evidence regarding the clinical features of IIE in children." | 2.90 | Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy. ( Honda, T; Ide, Y; Kubota, N; Nakamura, T; Sakashita, K; Tozuka, M; Yanagisawa, R, 2019) |
| "Prolonged encephalopathy and MB therapy has not been described in the literature as lasting longer than 30 days following treatment." | 2.82 | A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature. ( Campino, GA; Chain, G; Kalia, M; Kestenbaum, K; Pappas, L; Sechser-Perl, A; Zaghloul, N, 2022) |
| "Ifosfamide is an important part of chemotherapeutic regimens used to treat a variety of malignancies." | 2.43 | Evaluating risk factors for the development of ifosfamide encephalopathy. ( David, KA; Picus, J, 2005) |
| "Two developed milder encephalopathy; one had no CNS depression at all." | 2.41 | Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. ( De Vos, F; Pelgrims, J; Prové, A; Schrijvers, D; Van den Brande, J; Vermorken, JB, 2000) |
| "We describe an episode of encephalopathy developed at the third cycle of ifosfamide treatment in a child with Ewing sarcoma." | 1.72 | Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case. ( Anlar, B; Aydin, B; Günbey, C; Müngen, E; Öz, S; Yaman Bajin, İ, 2022) |
| "Ifosfamide-induced encephalopathy (IIE) is a rare and serious adverse reaction." | 1.62 | Methylene blue and ifosfamide-induced encephalopathy: Myth or reality? ( Abahssain, H; Errihani, H; Essangri, H; Fadhil, FZ; Guessous, F; Meddah, B; Moukafih, B; Mrabti, H; Souadka, A, 2021) |
| "Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pediatric oncology practice." | 1.62 | Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer. ( Ataseven, E; Göktepe, ŞÖ; Kantar, M, 2021) |
| "Ifosfamide-related encephalopathy commonly results in a distinct pattern of generalized periodic discharges admixed with intermittent background attenuation on EEG." | 1.51 | Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy. ( Chen, X; Gusdon, AM; Malani, R, 2019) |
| "Ifosfamide-induced encephalopathy occurred in 11 patients (5." | 1.51 | Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®). ( Chambord, J; Demore, B; Henny, F; Hombourger, B; Lider, P; Rios, M; Salleron, J; Vallance, C; Vigneron, J, 2019) |
| "Ifosfamide (IFA) is a potent alkylating antitumoral agent, but its use is limited by neurological side effects." | 1.48 | Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases. ( Bellien, J; Duflot, T; Filhon, B; Joannidès, R; Lamoureux, F; Marie-Cardine, A; Massy-Guillemant, N; Pereira, T; Verstuyft, C, 2018) |
| "Ifosfamid-related encephalopathy (IRE) is a rare but severe adverse event, without clearly identified risk factors." | 1.46 | [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients]. ( Defachelles, AS; Deplanque, D; Lervat, C; Marliot, G; Penel, N; Peugniez, C; Ryckewaert, T; Sakji, I; Stern, N, 2017) |
| " In contrast to previous studies, ifosfamide dosage and brain metastasis are not significant contributing factors." | 1.43 | Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis. ( Chen, WH; Dong, YH; Lo, Y; Shen, LJ; Wu, FL, 2016) |
| "Methylene blue and thiamine have been occasionally successful as treatment." | 1.43 | The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report. ( HaDuong, JH; Yeo, KK, 2016) |
| "Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers." | 1.40 | Ifosfamide related encephalopathy: the need for a timely EEG evaluation. ( Feyissa, AM; Tummala, S, 2014) |
| "Ifosfamide is an alkylating agent used to treat different types of malignancies including lymphomas, sarcomas and germinal cell tumors." | 1.39 | Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report. ( Bhardwaj, H; Cherry, MA; Hopps, S; Pant, S; Srour, S, 2013) |
| "Methylene blue has been used not only as a diagnostic agent, but also as an agent in the treatment of ifosfamide-induced encephalopathy (IIE) for several years." | 1.38 | Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy. ( Fisher, DC; McDonnell, AM; Rybak, I; Wadleigh, M, 2012) |
| "Ifosfamide is a widely used chemotherapeutic agent for the treatment of a broad spectrum of solid tumors." | 1.36 | Ifosfamide-induced encephalopathy and movement disorder. ( Ames, B; Chaffee, S; Kim, J; Lewis, LD; Morse, R, 2010) |
| "Ifosfamide is an oxazophosphorine widely used in the treatment of cancer in children and adults." | 1.30 | Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. ( Foxall, PJ; Hartley, JM; Lapsley, M; Neild, GH; Nicholson, JK; Singer, JM; Souhami, RL, 1997) |
| "Ifosfamide-related encephalopathy has polymorphous and non-specific clinical picture." | 1.30 | [Ifosfamide-related encephalopathy. Report of two cases]. ( Coutant, G; Daly, JP; Desrame, J; Dourthe, LM; Merrer, J, 1999) |
| "The authors report a case of encephalopathy after treatment with ifosfamide treated by a methylene blue infusion." | 1.29 | [Treatment of ifosfamide induced encephalopathy with methylene-blue]. ( Dreyfus, G; Eftekari, P; Ferrero, JM; Largillier, R; Namer, M, 1995) |
| "Acute encephalopathy following treatment with ifosfamide and mesna was observed in 5 (4 women and 1 men) of 28 patients (17." | 1.28 | Encephalopathy in ifosfamide-treated patients. ( Chaitchik, S; Merimsky, O; Reider-Groswasser, I; Wigler, N, 1992) |
| "We describe a case of reversible encephalopathy caused by the recently released anticancer drug Ifosfamide." | 1.28 | Ifosfamide encephalopathy. ( Beydoun, SR; Danesh, MM; De Giorgio, CM; Kemp, RA, 1989) |
| "Eighteen consecutive cases of encephalopathy occurring after ifosfamide/mesna chemotherapy were prospectively assessed." | 1.28 | Ifosfamide encephalopathy: a reappraisal. ( Green, JA; Husband, DJ; Warenius, HM; Watkin, SW, 1989) |
| "Ifosfamide and mesna were administered to 77 patients with advanced malignancies." | 1.27 | Prediction of ifosfamide/mesna associated encephalopathy. ( Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA, 1986) |
| "A case of reversible encephalopathy after one dose of ifosfamide/mesna in an epileptic 15-year-old girl is reported." | 1.27 | Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. ( Carde, P; Droz, JP; Flamant, F; Friedman, S; Ghosn, M; Hayat, M; Leclerq, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (17.39) | 18.7374 |
| 1990's | 24 (34.78) | 18.2507 |
| 2000's | 7 (10.14) | 29.6817 |
| 2010's | 17 (24.64) | 24.3611 |
| 2020's | 9 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Chain, G | 1 |
| Kalia, M | 1 |
| Kestenbaum, K | 1 |
| Pappas, L | 1 |
| Sechser-Perl, A | 1 |
| Campino, GA | 1 |
| Zaghloul, N | 1 |
| Müngen, E | 1 |
| Yaman Bajin, İ | 1 |
| Öz, S | 1 |
| Günbey, C | 1 |
| Anlar, B | 1 |
| Aydin, B | 1 |
| Idle, JR | 2 |
| Beyoğlu, D | 1 |
| Sano, T | 1 |
| Setsu, N | 1 |
| Kobayashi, E | 1 |
| Kawai, A | 1 |
| Ide, Y | 1 |
| Yanagisawa, R | 1 |
| Kubota, N | 1 |
| Sakashita, K | 1 |
| Tozuka, M | 1 |
| Nakamura, T | 1 |
| Honda, T | 1 |
| Sarbay, H | 1 |
| Demir, ÜF | 1 |
| Yılmaz, G | 1 |
| Atay, AA | 1 |
| Malbora, B | 1 |
| Abahssain, H | 1 |
| Moukafih, B | 1 |
| Essangri, H | 1 |
| Mrabti, H | 1 |
| Meddah, B | 1 |
| Guessous, F | 1 |
| Fadhil, FZ | 1 |
| Souadka, A | 1 |
| Errihani, H | 1 |
| Modi, JN | 1 |
| Cimino, SK | 1 |
| Ataseven, E | 1 |
| Göktepe, ŞÖ | 1 |
| Kantar, M | 1 |
| Duflot, T | 1 |
| Marie-Cardine, A | 1 |
| Verstuyft, C | 1 |
| Filhon, B | 2 |
| Pereira, T | 1 |
| Massy-Guillemant, N | 1 |
| Joannidès, R | 1 |
| Bellien, J | 1 |
| Lamoureux, F | 1 |
| Gharaibeh, EZ | 1 |
| Telfah, M | 1 |
| Powers, BC | 1 |
| Salacz, ME | 1 |
| Gusdon, AM | 1 |
| Malani, R | 1 |
| Chen, X | 1 |
| Chambord, J | 1 |
| Henny, F | 1 |
| Salleron, J | 1 |
| Hombourger, B | 1 |
| Lider, P | 1 |
| Vigneron, J | 1 |
| Demore, B | 1 |
| Vallance, C | 1 |
| Rios, M | 1 |
| Lentz, KL | 1 |
| Clark, SM | 1 |
| Ayarza, M | 1 |
| Liu, B | 1 |
| Morgan, KP | 1 |
| Wind, LS | 1 |
| Hairston, A | 1 |
| Feyissa, AM | 1 |
| Tummala, S | 1 |
| Robert, G | 1 |
| Chappé, C | 1 |
| Taque, S | 1 |
| Bruneau, B | 1 |
| Gandemer, V | 1 |
| Szabatura, AH | 1 |
| Cirrone, F | 1 |
| Harris, C | 1 |
| McDonnell, AM | 2 |
| Feng, Y | 1 |
| Voit, D | 1 |
| Neuberg, D | 1 |
| Butrynski, J | 1 |
| Fisher, DC | 2 |
| Miri-Aliabad, G | 1 |
| Lo, Y | 1 |
| Shen, LJ | 1 |
| Chen, WH | 1 |
| Dong, YH | 1 |
| Wu, FL | 1 |
| Lacarra, B | 1 |
| Hervouet, C | 1 |
| Jaffray, M | 1 |
| Schneider, P | 1 |
| Vannier, JP | 1 |
| Tsukamoto, S | 1 |
| Kurematsu, Y | 1 |
| Honoki, K | 1 |
| Kido, A | 1 |
| Somekawa, S | 1 |
| Kaya, D | 1 |
| Sadamitsu, T | 1 |
| Fukui, H | 1 |
| Tanaka, Y | 1 |
| Yeo, KK | 1 |
| HaDuong, JH | 1 |
| Stern, N | 1 |
| Sakji, I | 1 |
| Defachelles, AS | 1 |
| Lervat, C | 1 |
| Ryckewaert, T | 1 |
| Marliot, G | 1 |
| Peugniez, C | 1 |
| Deplanque, D | 1 |
| Penel, N | 1 |
| Sweiss, KI | 1 |
| Beri, R | 1 |
| Shord, SS | 1 |
| Ames, B | 1 |
| Lewis, LD | 2 |
| Chaffee, S | 1 |
| Kim, J | 1 |
| Morse, R | 1 |
| Rybak, I | 1 |
| Wadleigh, M | 1 |
| Cherry, MA | 1 |
| Bhardwaj, H | 1 |
| Hopps, S | 1 |
| Srour, S | 1 |
| Pant, S | 1 |
| Buesa, JM | 1 |
| García-Teijido, P | 1 |
| Losa, R | 1 |
| Fra, J | 1 |
| David, KA | 1 |
| Picus, J | 1 |
| Lerch, S | 1 |
| Küpfer, A | 6 |
| Lauterburg, BH | 1 |
| Durand, JP | 1 |
| Gourmel, B | 1 |
| Mir, O | 1 |
| Goldwasser, F | 1 |
| Aeschlimann, C | 3 |
| Wermuth, B | 1 |
| Cerny, T | 5 |
| Le Cesne, A | 1 |
| Antoine, E | 1 |
| Spielmann, M | 1 |
| Le Chevalier, T | 1 |
| Brain, E | 1 |
| Toussaint, C | 1 |
| Janin, N | 1 |
| Kayitalire, L | 1 |
| Fontaine, F | 1 |
| Genin, J | 1 |
| Ferrero, JM | 1 |
| Eftekari, P | 1 |
| Largillier, R | 1 |
| Dreyfus, G | 1 |
| Namer, M | 1 |
| Cain, JW | 1 |
| Bender, CM | 1 |
| Zulian, GB | 1 |
| Tullen, E | 1 |
| Maton, B | 1 |
| Gilbert, GJ | 1 |
| Simonian, NA | 1 |
| Gilliam, FG | 1 |
| Chiappa, KH | 1 |
| Cameron, JC | 1 |
| Demandt, M | 1 |
| Wandt, H | 1 |
| Alonso, JL | 1 |
| Nieto, Y | 1 |
| López, JA | 1 |
| Martín, M | 1 |
| Díaz-Rubio, E | 1 |
| Koschuth, A | 1 |
| Späth-Schwalbe, PE | 1 |
| Possinger, K | 1 |
| Foxall, PJ | 1 |
| Singer, JM | 1 |
| Hartley, JM | 1 |
| Neild, GH | 1 |
| Lapsley, M | 1 |
| Nicholson, JK | 1 |
| Souhami, RL | 1 |
| Gurm, HS | 1 |
| Budd, GT | 1 |
| Dourthe, LM | 1 |
| Coutant, G | 1 |
| Desrame, J | 1 |
| Merrer, J | 1 |
| Daly, JP | 1 |
| Pelgrims, J | 1 |
| De Vos, F | 1 |
| Van den Brande, J | 1 |
| Schrijvers, D | 1 |
| Prové, A | 1 |
| Vermorken, JB | 1 |
| Jain, S | 1 |
| Moger, V | 1 |
| Kumari, S | 1 |
| Varma, S | 1 |
| Merimsky, O | 2 |
| Reider-Groswasser, I | 2 |
| Wigler, N | 1 |
| Chaitchik, S | 2 |
| Inbar, M | 1 |
| Scharf, M | 1 |
| Goldsmith, K | 1 |
| Castiglione, M | 1 |
| Brunner, K | 1 |
| Martinelli, G | 1 |
| Lind, M | 1 |
| Antman, KH | 1 |
| Elias, A | 1 |
| Ryan, L | 1 |
| Cantwell, BM | 2 |
| Idle, M | 1 |
| Millward, MJ | 1 |
| Hall, G | 1 |
| Lind, MJ | 1 |
| Verdeguer, A | 1 |
| Castel, V | 1 |
| Esquembre, C | 1 |
| Ferris, J | 1 |
| Fernandez, JM | 1 |
| Ruiz, JG | 1 |
| Danesh, MM | 1 |
| De Giorgio, CM | 1 |
| Beydoun, SR | 1 |
| Kemp, RA | 1 |
| Watkin, SW | 1 |
| Husband, DJ | 1 |
| Green, JA | 1 |
| Warenius, HM | 1 |
| Meanwell, CA | 3 |
| Blake, AE | 2 |
| Latief, TN | 1 |
| Blackledge, G | 3 |
| Mould, JJ | 1 |
| Blake, DR | 1 |
| Shaw, IC | 1 |
| Honigsberger, L | 2 |
| Spooner, D | 1 |
| Williams, AC | 1 |
| Harris, AL | 1 |
| Kelly, KA | 2 |
| Perren, TJ | 1 |
| Turner, RC | 1 |
| Smith, IE | 1 |
| Beuzeboc, P | 1 |
| Dorval, T | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Palangie, T | 1 |
| Scholl, S | 1 |
| Pouillart, P | 1 |
| Salloum, E | 1 |
| Flamant, F | 2 |
| Ghosn, M | 2 |
| Taleb, N | 1 |
| Akatchereian, C | 1 |
| Carde, P | 1 |
| Leclerq, B | 1 |
| Friedman, S | 1 |
| Droz, JP | 1 |
| Hayat, M | 1 |
7 reviews available for ifosfamide and Brain Diseases
| Article | Year |
|---|---|
A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature.
Topics: Brain Diseases; Child; Female; Humans; Ifosfamide; Methylene Blue; Neurotoxicity Syndromes; Sleepine | 2022 |
Ifosfamide - History, efficacy, toxicity and encephalopathy.
Topics: Antineoplastic Agents; Brain Diseases; Cyclophosphamide; Humans; Ifosfamide; Methylene Blue | 2023 |
Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
Topics: Adult; Albumins; Antineoplastic Agents, Alkylating; Bilirubin; Brain Diseases; Cohort Studies; Enzym | 2008 |
Evaluating risk factors for the development of ifosfamide encephalopathy.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antineoplastic Agents, Alkylating; Brain Diseases; Cohort Stud | 2005 |
Ifosfamide-induced neurotoxicity: associated symptoms and nursing implications.
Topics: Brain Diseases; Cognition Disorders; Female; Humans; Ifosfamide; Middle Aged; Oncology Nursing; Ovar | 1995 |
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Dose-Response Relationsh | 2000 |
Ifosfamide pharmacokinetics.
Topics: Administration, Oral; Aging; Brain Diseases; Dose-Response Relationship, Drug; Humans; Ifosfamide | 1991 |
3 trials available for ifosfamide and Brain Diseases
| Article | Year |
|---|---|
Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Child; Child, Preschool | 2019 |
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Dacarbazine; Doxorubici | 1995 |
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Chil | 1990 |
59 other studies available for ifosfamide and Brain Diseases
| Article | Year |
|---|---|
Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Child; Cisplatin; Creatinine; Humans; Ifosfamide; | 2022 |
[Errata: A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant].
Topics: Antiemetics; Aprepitant; Brain Diseases; Drug Interactions; Humans; Ifosfamide | 2023 |
Ifosfamide induced encephalopathy in a child with osteosarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Female; Humans; Ifosf | 2021 |
Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Diseases; Creatinine; Drug-Related Side Effect | 2021 |
Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant.
Topics: Adult; Brain Diseases; Humans; Ifosfamide; Incidence; Morpholines; Retrospective Studies; Sarcoma | 2021 |
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Diseases; Child; Female; Humans; Ifosfamide; Me | 2021 |
Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.
Topics: Administration, Intravenous; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Di | 2018 |
Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Etoposide; Female; Humans; Ifosfamid | 2019 |
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Electroencephalography; | 2019 |
Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®).
Topics: Adult; Aged; Brain Diseases; Drugs, Generic; Female; France; Humans; Ifosfamide; Incidence; Male; Mi | 2019 |
Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cohort Studies; Etoposi | 2020 |
Ifosfamide related encephalopathy: the need for a timely EEG evaluation.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Diseases; Electroencephalography; Female; Humans; If | 2014 |
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Huma | 2014 |
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Cancer Care Facilities; Cisplatin; Female; Humans | 2015 |
Green urine secondary to methylene blue.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2014 |
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Creatinine; Female; Humans; Ifosfami | 2016 |
Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Diseases; Chemistry, Pharmaceutical; Child; Chi | 2016 |
Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Diabetes Insipidus, Neurogenic; Doxo | 2016 |
The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Child; Female; Hemodiafiltration; Humans; Ifosfam | 2016 |
[Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Diseases; Ch | 2017 |
Ifosfamide-induced encephalopathy and movement disorder.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Child; Female; Humans | 2010 |
Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy.
Topics: Brain Diseases; Humans; Ifosfamide; Methylene Blue; Serotonin Syndrome | 2012 |
Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Ly | 2013 |
Treatment of ifosfamide encephalopathy with intravenous thiamin.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Infusions, Intravenous | 2003 |
Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Diseases; Carbocysteine; Drug Interactions; | 2006 |
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Diseases; Cytochrome P-450 CYP3A; | 2007 |
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.
Topics: Administration, Oral; Adolescent; Antidotes; Bone Neoplasms; Brain Diseases; Drug Overdose; Female; | 1994 |
[Treatment of ifosfamide induced encephalopathy with methylene-blue].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Methylene Blue; | 1995 |
Methylene blue for ifosfamide-associated encephalopathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carcinoma, Squamous Cell; Cisp | 1995 |
Diazepam-sensitive encephalopathy.
Topics: Brain Diseases; Dialysis; Diazepam; Humans; Ifosfamide | 1994 |
Ifosfamide causes a diazepam-sensitive encephalopathy.
Topics: Adult; Brain Diseases; Consciousness; Diazepam; Electroencephalography; Female; Humans; Ifosfamide; | 1993 |
Ifosfamide neurotoxicity. A challenge for nurses, a potential nightmare for patients.
Topics: Brain Diseases; Carcinoma, Small Cell; Central Nervous System; Female; Humans; Ifosfamide; Lung Neop | 1993 |
[Successful treatment with methylene blue of ifosfamide-induced central nervous system effects].
Topics: Antidotes; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Male; Methylene Bl | 1996 |
Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy.
Topics: Administration, Oral; Animals; Antidotes; Antineoplastic Agents, Alkylating; Brain Diseases; Drug Th | 1996 |
Ifosfamide encephalopathy and methylene-blue: a case report.
Topics: Brain Diseases; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged | 1996 |
[Methylene blue in ifosfamide-induced encephalopathy].
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Methylene Blue; Middl | 1996 |
Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue.
Topics: Alkylation; Animals; Antidotes; Antineoplastic Agents; Brain Diseases; Cattle; Ifosfamide; In Vitro | 1996 |
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Topics: Adult; Amino Acids; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocol | 1997 |
A 47-year-old man with leiomyosarcoma and altered mental status.
Topics: Brain Diseases; Fatal Outcome; Humans; Ifosfamide; Leiomyosarcoma; Male; Methylene Blue; Middle Aged | 1999 |
[Ifosfamide-related encephalopathy. Report of two cases].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Dise | 1999 |
Ifosfamide induced encephalopathy following chemotherapy of Non-Hodgkin's Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Lymphoma, Non-H | 2001 |
The enigma of ifosfamide encephalopathy.
Topics: Acetaldehyde; Brain; Brain Diseases; Drug Administration Schedule; Female; Humans; Ifosfamide | 1992 |
Encephalopathy in ifosfamide-treated patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Female; Humans; Ifosfam | 1992 |
Ifosfamide-related acute encephalopathy: clinical and radiological aspects.
Topics: Aged; Aged, 80 and over; Brain; Brain Diseases; Female; Humans; Ifosfamide; Tomography, X-Ray Comput | 1991 |
Ifosfamide administration recommendation questioned.
Topics: Brain Diseases; Humans; Ifosfamide; Infusions, Intravenous | 1991 |
Ifosfamide by continuous infusion to prevent encephalopathy.
Topics: Brain Diseases; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Humans; If | 1990 |
Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion.
Topics: Arginine Vasopressin; Brain Diseases; Female; Humans; Hyponatremia; Ifosfamide; Infusions, Intraveno | 1990 |
Fatal encephalopathy with ifosfamide/mesna.
Topics: Brain Diseases; Child; Drug Therapy, Combination; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; | 1989 |
Ifosfamide encephalopathy.
Topics: Brain Diseases; Electroencephalography; Female; Humans; Ifosfamide; Middle Aged; Risk Factors | 1989 |
Ifosfamide encephalopathy: a reappraisal.
Topics: Adult; Aged; Brain Diseases; Confusion; Female; Humans; Hypokalemia; Ifosfamide; Male; Middle Aged; | 1989 |
Encephalopathy associated with ifosphamide/mesna therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Female; Humans; If | 1985 |
Ifosfamide/mesa and encephalopathy.
Topics: Brain Diseases; Carcinoma, Small Cell; Cyclophosphamide; Female; Humans; Ifosfamide; Lung Neoplasms; | 1985 |
Ifosfamide, mesna, and encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Cyclophosphamide; Fema | 1985 |
Avoiding ifosfamide/mesna encephalopathy.
Topics: Adolescent; Adult; Aged; Brain Diseases; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male | 1986 |
Encephalopathy with rapid infusion ifosfamide/mesna.
Topics: Brain Diseases; Drug Therapy, Combination; Humans; Ifosfamide; Infusions, Intravenous; Mercaptoethan | 1987 |
[Encephalopathy caused by an ifosfamide-mesna combination].
Topics: Adult; Brain Diseases; Drug Therapy, Combination; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna | 1988 |
Prediction of ifosfamide/mesna associated encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Electroencephalography; Female; Huma | 1986 |
Irreversible encephalopathy with ifosfamide/mesna.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child, Preschool; Dactinomycin; Fema | 1987 |
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
Topics: Adolescent; Brain Diseases; Drug Interactions; Drug Therapy, Combination; Epilepsy; Female; Humans; | 1988 |